Artal Group S.A. Crispr Therapeutics Ag Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $4.1 Million - $5.26 Million	-100,000 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$35.45 - $48.2 $1.6 Million - $2.17 Million	-45,000 Reduced 31.03%	100,000 $4.71 Million
Q4 2018 Feb 11, 2019	BUY	$22.73 - $42.34 $1.02 Million - $1.91 Million	45,000 Added 45.0%	145,000 $4.14 Million
Q3 2018 Nov 09, 2018	BUY	$44.35 - $65.71 $2.22 Million - $3.29 Million	50,000 Added 100.0%	100,000 $4.44 Million
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $1.07 Million - $1.84 Million	25,000 Added 100.0%	50,000 $2.94 Million
Q1 2018 May 10, 2018	SELL	$23.52 - $58.17 $588,000 - $1.45 Million	-25,000 Reduced 50.0%	25,000 $1.14 Million
Q4 2017 Feb 09, 2018	BUY	$16.95 - $23.48 $847,500 - $1.17 Million	50,000	50,000 $1.17 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.48B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.